Physician profile
Erika Mitchell
NPI 1962612655
$5,537.53
in general payments reported to CMS, 2019-2025
12 companies · $19.11 in 2025
The $19.11 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,615 · 2022: $889 · 2024: $14.69 · 2025: $19.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,390.81 | 2021-2022 | |
| Biogen, INC. | $1,035.56 | 2021-2022 | |
| Celgene Corporation | $900.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $375.00 | 2021 | |
| Allergan, INC. | $158.87 | 2021-2022 | |
| Abbvie INC. | $153.99 | 2022 | |
| Emd Serono, INC. | $134.35 | 2022-2025 | |
| Genentech USA, INC. | $116.38 | 2022 | |
| Amneal Pharmaceuticals LLC | $85.92 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $85.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $77.30 | 2022 | |
| Neurocrine Biosciences, INC. | $24.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.